<DOC>
	<DOCNO>NCT01701986</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose gemcitabine ( 6 possible dos ) give combination busulfan clofarabine allogeneic stem cell transplant . Researchers also want learn combination help control lymphoma . The safety treatment also study . Busulfan design bind DNA ( genetic material cell ) , may cause cancer cell die . It commonly use stem cell transplant . Clofarabine gemcitabine design block growth cancer cell , may cause cancer cell die .</brief_summary>
	<brief_title>Gemcitabine/Clofarabine/Busulfan Allogeneic Transplantation Aggressive Lymphomas</brief_title>
	<detailed_description>Study Drug Administration Pharmacokinetic ( PK ) Testing : The day receive stem cell call minus day , Day -2 , Day -1 . The day receive stem cell call Day 0 . The day receive stem cell call plus day , Day +1 , Day +2 . Between Days -15 -8 , receive low-level `` test '' dose busulfan vein 45 minute 1 hour . Test dos use study body break busulfan decide dose busulfan receive . You may receive test dose Day -8 outpatient clinic , Day -8 inpatient hospital . Blood ( 1 teaspoon time ) drawn PK test 11 time 11 hour busulfan test dose . PK test measure amount study drug body different time point . The study staff tell PK test schedule . A heparin lock line place vein PK test low number needle stick need draws . If reason possible PK test perform , receive standard dose busulfan . On Day -9 Day -7 , admit hospital give fluid vein hydrate . On Days -6 -4 , receive gemcitabine vein 40-180 minute . The dose receive base join study . The length time take infuse gemcitabine base join study dose amount assign . Up 6 dose level gemcitabine test . Up 3 participant enrol dose level . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose gemcitabine find . After high dose find , additional participant enrol dose . The number patient group receive high tolerable dose depend many enrolled group . On Days -6 -3 , receive clofarabine vein 1 hour , follow dose busulfan vein 3 hour . If reason could PK test perform , receive standard busulfan dose day . On Days -3 -1 , stem cell donor relate , receive antithymocyte globulin ( ATG ) vein 4 hour day . ATG design weaken immune system order low risk body reject transplant . If stem cell donor relate , receive drug . Beginning Day -2 , receive tacrolimus vein 24 hour every day able take mouth . Tacrolimus design weaken immune system low risk graft-versus-host-disease ( GVHD - reaction donor 's immune cell body ) . After able take tacrolimus mouth , take every day 6 month , doctor think safe stop . On Day 0 , receive donor 's stem cell vein . The infusion last anywhere 30 minute several hour . After stem cell infusion , begin receive mycophenolate mofetil ( MMF ) vein 2 hour , 3 time day . When doctor think tolerate take mouth , switch take MMF mouth 3 time day food . If GVHD Day 60 , MMF stop . If miss dose MMF tell study doctor . You try make dose later . If develop GVHD , may take MMF long period time . Starting 1 week transplant ( Day +7 ) , receive filgrastim ( G-CSF ) injection skin 1 time day blood cell level return normal . Filgrastim design make white blood cell grow , may help fight infection . You may give standard drug help low risk side effect . Also , doctor think appropriate base CD20 protein specific blood cell ( CD20+ disease ) , receive standard therapy rituximab . You may ask study staff information drug give risk . Study Visits : About 30 day receive stem cell , compute tomography ( CT ) and/or positron emission tomography ( PET ) scan check status disease . About 4 week stem cell transplant : - You physical exam , include measurement height , weight , vital sign ( blood pressure , heart rate , temperature , breathe rate ) . - You ask feel side effect may . - You check possible reaction study treatment , include GVHD . - Blood ( 4 tablespoon ) draw routine test , see transplant take , check status disease . Follow-Up Visits : About 3 , 6 , 12 month transplant , every 6 month 4 year : - You physical exam , include measurement vital sign . - You ask feel side effect may . - You check possible reaction treatment , include GVHD . - Blood ( 4 tablespoon ) draw routine test , see well transplant take , check status disease . - At point doctor think need , bone marrow aspiration CT and/or PET scan check status disease . To collect bone marrow aspirate , area hip site numb anesthetic , small amount bone marrow withdrawn large needle . The study staff also stay contact local doctor find disease come back check . Length Treatment : You study 5 year . After 1 year , study specific test required complete . Your transplant doctor perform routine standard care follow-up patient receive allogeneic stem cell transplantation receive . You may remove study early doctor think best interest , disease get bad come back , intolerable side effect occur , graft failure ( transplanted cell grow ) , unable follow study direction . If reason want leave study early , must talk study doctor . It may life-threatening leave study start receive study drug receive stem cell transplant blood cell count dangerously low . This investigational study . Gemcitabine clofarabine FDA approve commercially available treatment lymphoma . Busulfan FDA approve commercially available use stem cell transplantation . The combination gemcitabine give combination busulfan clofarabine allogeneic stem cell transplant investigational . Up 30 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Age 12 65 year age . 2 . Patients refractory Bcell Tcell nonHodgkin 's lymphoma Hodgkin 's lymphoma eligible allogeneic transplantation . 3 . An 8/8 HLA match ( high resolution type A , B , C , DRB1 ) sibling unrelated donor . 4 . Left ventricular EF &gt; /= 45 % . 5 . FEV1 , FVC correct DLCO &gt; /= 50 % . 6 . Adequate renal function , define estimate serum creatinine clearance &gt; /=50 ml/min ( use CockcroftGault formula : creatinine clearance = [ ( 140age ) *kg/ ( 72*serum creatinine ) ] * 0.85 female ) and/or serum creatinine &lt; /=1.6 mg/dL . 7 . Serum bilirubin &lt; /= 2x upper limit normal . 8 . SGPT &lt; /= 2x upper limit normal . 9 . Voluntary sign IRBapproved informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . 10 . Men woman reproductive potential must agree follow accepted birth control method duration study . Female subject either postmenopausal surgically sterilize willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Male subject agrees use acceptable method contraception duration study . 1 . Patient active CNS disease . 2 . Pregnancy ( positive Beta HCG test woman child bear potential define postmenopausal 12 month previous surgical sterilization ) currently breastfeed . Pregnancy test require postmenopausal surgically sterilize woman . 3 . Active hepatitis B , either active carrier ( HBsAg + ) viremic ( HBV DNA &gt; /=10,000 copies/mL , &gt; /= 2,000 IU/mL ) . 4 . Evidence either cirrhosis stage 34 liver fibrosis patient chronic hepatitis C positive hepatitis C serology . 5 . HIV infection . 6 . Active uncontrolled bacterial , viral fungal infection . 7 . Exposure investigational drug within 4 week enrollment . 8 . Grade &gt; /= 3 nonhematologic toxicity previous therapy resolve &lt; /= grade 1 . 9 . Radiation therapy head neck ( exclude eye ) , internal organ chest , abdomen pelvis month prior enrollment . 10 . Prior whole brain irradiation . 11 . Prior autologous SCT prior 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Aggressive lymphoma</keyword>
	<keyword>Allogeneic stem-cell transplant</keyword>
	<keyword>alloSCT</keyword>
	<keyword>Refractory B-cell</keyword>
	<keyword>T-cell</keyword>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
	<keyword>Hodgkin 's lymphoma</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemcitabine Hydrochloride</keyword>
	<keyword>Gemzar</keyword>
	<keyword>Clofarabine</keyword>
	<keyword>Clofarex</keyword>
	<keyword>Clolar</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Anti-Thymocyte Globulin</keyword>
	<keyword>ATG</keyword>
	<keyword>Thymoglobulin</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
	<keyword>Mycophenolate Mofetil</keyword>
	<keyword>MMF</keyword>
	<keyword>CellCept</keyword>
</DOC>